Immatics N.V. (IMTX)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
As of 11:43AM EDT. Market open.
| Previous close | 10.15 |
| Open | 10.25 |
| Bid | 9.81 x 400 |
| Ask | 9.94 x 200 |
| Day's range | 9.67 - 10.04 |
| 52-week range | 6.46 - 13.16 |
| Volume | |
| Avg. volume | 434,904 |
| Market cap | 1.017B |
| Beta (5Y monthly) | 0.68 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.28 |
| Earnings date | 14 May 2024 - 20 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 18.77 |
GlobeNewswireImmatics Announces Full Year 2023 Financial Results and Corporate Update
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objective response rate with median duration of response not reached at median follow-up of 14.4 months; IMA203 was well toleratedRegistration-enabling randomized Phase 2/3 trial for ACTengine® IMA203 GEN1 in 2L+ melanoma planned to begin in 2024 Next data update on IMA203 GEN1 and IMA203CD8 GEN2 planned for 2H 2024 First clinical data updates for Immatics’ next-generation TCR Bispe
Simply Wall St.With 52% institutional ownership, Immatics N.V. (NASDAQ:IMTX) is a favorite amongst the big guns
Key Insights Institutions' substantial holdings in Immatics implies that they have significant influence over the...
- Simply Wall St.
Immatics' (NASDAQ:IMTX) investors will be pleased with their notable 35% return over the last year
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But if you pick...
© 2024 Yahoo. All rights reserved.